Travere Therapeutics swings to Q3 net loss of $52.34 million

Travere Therapeutics reported third-quarter 2026 revenue of $224.6 million, compared with $164.9 million a year earlier, and a GAAP net loss of $52.3 million. FILSPARI sales continued to expand across IgAN and FSGS, while the company advanced its clinical programs and reported cash, cash equivalent…